deltatrials
Completed PHASE2 INTERVENTIONAL 6-arm NCT04176250

Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis

A Phase 2a, Dose Escalation, Controlled, Randomized Study to Evaluate Safety, Early Bactericidal Activity (EBA) and Pharmacokinetics of TBA-7371 in Adult Patients With Rifampicin-sensitive Pulmonary Tuberculosis

Sponsor: Gates Medical Research Institute

Conditions Pulmonary Tuberculosis
Interventions HRZE TBA-7371
Updated 18 times since 2019 Last updated: Oct 4, 2023 Started: Jan 16, 2020 Primary completion: Oct 5, 2022 Completion: Oct 5, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Pulmonary Tuberculosis, this trial is completed. The trial is conducted by Gates Medical Research Institute and has accumulated 18 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Sep 2020 · 5 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~Dec 2022 · 5 months · monthly snapshot~Dec 2022 – ~May 2024 · 17 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Aug 2025 · 11 months · monthly snapshot~Aug 2025 – present · 11 months · monthly snapshot

Change History

18 versions recorded

  1. Aug 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Aug 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. May 2024 — Jul 2024 [monthly]

    Completed PHASE2

  5. Dec 2022 — May 2024 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

▶ Show 13 earlier versions

  1. Jul 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  2. Apr 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  3. Sep 2021 — Apr 2022 [monthly]

    Recruiting PHASE2

  4. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  5. Apr 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  6. Feb 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  7. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  8. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  9. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

    Status: Suspended → Recruiting

  10. Apr 2020 — Sep 2020 [monthly]

    Suspended PHASE2

    Status: Recruiting → Suspended

  11. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  12. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  13. Dec 2019 — Feb 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gates Medical Research Institute
Data source: Gates Medical Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations